Ranbaxy Laboratories Limited announced the launch of its brand Soliten (Solifenacin), in the Indian market for the management of chronic urological disorder. Soliten will be sold in dosage forms of 5 mg and 10 mg tablets.

Soliten is a new and safer formulation that will provide effective relief from chronic problems of Overactive Bladder (OAB) which lead to symptoms such as inability to hold urine coupled with urgency and increased frequency to pass urine. The product is documented to have lesser side effects and greater effectiveness, a Ranbaxy press release said.

Commenting on the launch, Sanjeev I Dani, regional director, India & Middle East, Ranbaxy, said, "An overactive bladder largely remains untreated due to prevailing low awareness amongst its sufferers. The introduction of Soliten will strengthen the options available to urologists in treating the symptoms of this highly uncomfortable and annoying medical condition. The Ranbaxy Urology franchise has become a leader in its category in a short span of 3 years since its launch and the introduction of Soliten should help to further consolidate this position."

Speaking on the launch of Soliten, Dr Gopal Badlani, a leading Urologist from the Long Island Jewish Medical Centre, USA, said, " Solifenacin is a relatively new drug and has been present in the US for around 2 years. The drug has exhibited certain unique advantages over the current available therapy, which makes it different and an interest0ing new agent for the treatment of OAB with predominant urgency, a common ailment. It is being introduced in India soon after the international launch and will lead to significant improvement in the quality of life of patients suffering from the disease."
One out of every eleven individuals in the above 40 age group is believed to suffer from an Overactive Bladder. The problem is equally common in males as well as females and more dominant among the urban population.